Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 27Non-metastatic Castration-resistant Prostate Cancer 2Neoplasm Metastasis 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Metastatic 1Non-metastatic Prostate Cancer 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Low Risk Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Castration Levels of Testosterone 1Advanced Prostate Carcinoma 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × apalutamide × Clear all
NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

Phase 1 Completed
45 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡